Howlader NNA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER Cancer Statistics Review, 1975–2018. Bethesda: National Cancer Institute; 2021.

Google Scholar 

Eichhorst B, Ghia P, Niemann CU, et al. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024;35:762–8.

Article  CAS  PubMed  Google Scholar 

Wendtner C‑MOA‑S, Binder M, Dreger P, Eichhorst B, Gregor M, Greil R, Hallek M, Holtkamp U, Knauf WU, Pritzkuleit R, Schetelig J, Schwaner I, Staber PB, Wörmann B, Zenz T, Stilgenbauer S. Onkopedia-Leitlinie Chronische Lymphatische Leukämie. Onkopedia. 2024;.

Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96:1679–705.

Article  PubMed  Google Scholar 

Barr PM, Owen C, Robak T, et al. Up to 8‑year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:3440–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022;36:1171–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23:1031–43.

Article  CAS  PubMed  Google Scholar 

Seymour JF, Byrd JC, Ghia P, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023;142:687–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or Ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319–32.

Article  CAS  PubMed  Google Scholar 

Al-Sawaf O, Robrecht S, Zhang C, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6‑year results of the randomized phase 3 CLL14 study. Blood. 2024;144:1924–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niemann CU, Munir T, Moreno C, et al. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4‑year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:1423–33.

Article  CAS  PubMed  Google Scholar 

Fürstenau M, Kater AP, Robrecht S, et al. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4‑year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2024;25:744–59.

Article  PubMed  Google Scholar 

Woyach JA, Yin J, Brown JR, et al. Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance). JCO. 2023;41:7500–7500.

Article  Google Scholar 

Tausch E, Schneider C, Stilgenbauer S. Risk-stratification in frontline CLL therapy: standard of care. Hematology. 2024;2024:457–66.

Article  PubMed  PubMed Central  Google Scholar 

Simon F, Giza A, Robrecht S, et al. Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older. Leuk Lymphoma. 2022;63:3299–306.

Article  CAS  PubMed  Google Scholar 

Goede V, Cramer P, Busch R, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 2014;99:1095–100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strati P, Parikh SA, Chaffee KG, et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol. 2017;178:394–402.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gordon MJ, Churnetski M, Alqahtani H, et al. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 2018;124:3192–200.

Article  CAS  PubMed  Google Scholar 

O’Caoimh R, Sezgin D, O’Donovan MR, et al. Prevalence of frailty in 62 countries across the world: a systematic review and meta-analysis of population-level studies. Age Ageing. 2021;50:96–104.

Article  PubMed  Google Scholar 

Liu MA, DuMontier C, Murillo A, et al. Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood. 2019;134:374–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goede V, Neuendorff NR, Schulz R‑J, et al. Frailty assessment in the care of older people with haematological malignancies. Lancet Healthy Longev. 2021;2:e736–e45.

Article  PubMed  Google Scholar 

Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. Cmaj. 2005;173:489–95.

Article  PubMed  PubMed Central  Google Scholar 

Hamaker ME, Mitrovic M, Stauder R. The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy. Ann Hematol. 2014;93:1031–40.

Article  CAS  PubMed  Google Scholar 

Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging. 2012;16:601–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Michallet AS, Campidelli A, Lequeu H, et al. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group. Am J Hematol. 2017;92:E105–E7.

Article  PubMed  Google Scholar 

Eyre TA, Roeker LE, Fox CP, et al. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. Br J Haematol. 2020;188:918–23.

Article  CAS  PubMed  Google Scholar 

van der Straten L, Stege CAM, Kersting S, et al. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL. Blood. 2023;142:1131–42.

Article  PubMed  Google Scholar 

Simon F, Ligtvoet R, Bohn J‑P, et al. Efficacy and safety of acalabrutinib treatment in very old (≥ 80y) and/or frail patients with chronic lymphocytic leukemia (CLL)—primary endpoint analysis of the phase II CLL-frail trial. Blood. 2024;144:4618–4618.

Article  Google Scholar 

Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015;373:2425–37.

Article  CAS  PubMed  PubMed Central  Google Scholar